Drugs / MRG006A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07479485 | Apr 2026 → Apr 2028 expected | hepatocellular carcinoma | Lepu Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07093970 | Jul 2024 → Dec 2027 expected | cancer | Lepu Biopharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRG006A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07093970 ↗ |
| Route | Intravenous | “Administrated intravenously” NCT07093970 ↗ |